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Objectives The aim of this study was to test the hypothesis that elevated nonfasting remnant cholesterol is a causal risk
factor for ischemic heart disease independent of reduced high-density lipoprotein (HDL) cholesterol.
Background Elevated remnant cholesterol is associated with elevated levels of triglyceride-rich lipoproteins and with reduced
HDL cholesterol, and all are associated with ischemic heart disease.
Methods A total of 73,513 subjects from Copenhagen were genotyped, of whom 11,984 had ischemic heart disease diag-
nosed between 1976 and 2010. Fifteen genetic variants were selected, affecting: 1) nonfasting remnant choles-
terol alone; 2) nonfasting remnant cholesterol and HDL cholesterol combined; 3) HDL cholesterol alone; or
4) low-density lipoprotein (LDL) cholesterol alone as a positive control. The variants were used in a Mendelian
randomization design.
Results The causal odds ratio for a 1 mmol/l (39 mg/dl) genetic increase of nonfasting remnant cholesterol was 2.8
(95% confidence interval [CI]: 1.9 to 4.2), with a corresponding observational hazard ratio of 1.4 (95% CI: 1.3 to
1.5). For the ratio of nonfasting remnant cholesterol to HDL cholesterol, corresponding values were 2.9 (95% CI:
1.9 to 4.6) causal and 1.2 (95% CI 1.2 to 1.3) observational for a 1-U increase. However, for HDL cholesterol,
corresponding values were 0.7 (95% CI: 0.4 to 1.4) causal and 1.6 (95% CI: 1.4 to 1.7) observational for a
1 mmol/l (39 mg/dl) decrease. Finally, for LDL cholesterol, corresponding values were 1.5 (95% CI: 1.3 to 1.6)
causal and 1.1 (95% CI: 1.1 to 1.2) observational for a 1 mmol/l (39 mg/dl) increase.
Conclusions A nonfasting remnant cholesterol increase of 1 mmol/l (39 mg/dl) is associated with a 2.8-fold causal risk for
ischemic heart disease, independent of reduced HDL cholesterol. This implies that elevated cholesterol content
of triglyceride-rich lipoprotein particles causes ischemic heart disease. However, because pleiotropic effects of the
genetic variants studied cannot be totally excluded, these findings need to be confirmed using additional genetic vari-
ants and/or randomized intervention trials. (J Am Coll Cardiol 2013;61:427–36) © 2013 by the American
College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.08.1026n
cRemnant cholesterol is the cholesterol content of triglyceride-rich
lipoproteins, composed of very low-density lipoproteins and
intermediate-density lipoproteins in the fasting state and of
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in the nonfasting state (1,2). Elevated nonfasting plasma
triglyceride is a marker of elevated nonfasting remnant
cholesterol (1,3,4) and is associated with increased risk for
cardiovascular disease (1–7). Because triglycerides per se are
unlikely directly to cause cardiovascular disease (2,8), rem-
ant cholesterol is more likely to be the causal factor.
See page 437
Elevated remnant cholesterol is also associated with reduced
high-density lipoprotein (HDL) cholesterol (2,9,10); how-
ever, because HDL cholesterol increases have failed to
reduce cardiovascular disease (11,12), elevated remnant
holesterol may be a more likely causal factor than reduced
DL cholesterol.
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Remnants and Ischemic Heart Disease January 29, 2013:427–36We tested the hypothesis that
elevated nonfasting remnant cho-
lesterol is a causal risk factor for
ischemic heart disease indepen-
dent of reduced HDL cholesterol,
using the Mendelian randomiza-
tion approach (10,13,14): genetic
variants robustly associated with a
single lipoprotein, without effects on
other lipoproteins, were used to test the causal effect of lifelong
exposure on risk for ischemic heart disease. Following a pre-
specified plan and on the basis of current evidence from published
research, we therefore carefully selected 15 genetic variants affect-
ing levels of: 1) nonfasting remnant cholesterol alone; 2) nonfast-
ing remnant cholesterol and HDL cholesterol combined; 3)
HDL cholesterol alone; or 4) low-density lipoprotein (LDL)
cholesterol alone as a positive control. Thus, several other geno-
types were considered for inclusion but were a priori not included,
exemplified by apolipoprotein E genotypes that affect levels of all
the lipoproteins studied here and therefore would be difficult to
use for the present studies.
We genotyped 73,513 white subjects of Danish descent
from Copenhagen, of whom 11,984 had ischemic heart
disease. Causal estimates for each lipoprotein on risk for
ischemic heart disease were calculated in the same subjects
and were thus directly comparable.
Methods
Studies were approved by institutional review boards and
Danish ethical committees (H-KF-01-144/01, KF-
100.2039/91, KF-01-144/01, KA-93125, and KA-99039)
and conducted according to the Declaration of Helsinki.
Informed consent was obtained from participants. All par-
ticipants were white and of Danish descent. No subject was
included in more than 1 study.
The CGPS (Copenhagen General Population Study).
The CGPS is a prospective study of the general population
initiated in 2003 with ongoing enrollment (1). Subjects
were selected on the basis of the national Danish Civil
Registration System to reflect the adult Danish population
age 20 to 80 years. Data were obtained from a question-
naire, a physical examination, and blood samples including
deoxyribonucleic acid extraction. Follow-up was 100% com-
plete; that is, no subject was lost to follow-up. A total of
57,719 participants were included at the time of analyses; of
these, 10,368 were used as controls in the CIHDS (Copen-
hagen Ischemic Heart Disease Study), leaving 47,351
participants.
The CCHS (Copenhagen City Heart Study). The
CCHS is a prospective study of the general population
initiated from 1976 to 1978, with follow-up examinations
from 1981 to 1983, 1991 to 1994, and 2001 to 2003.
Participants were recruited and examined exactly as in the
CGPS. Blood samples for deoxyribonucleic acid extraction
Abbreviations
and Acronyms
CI  confidence interval
HDL  high-density
lipoprotein
LDL  low-density
lipoproteinwere drawn at the 1991 to 1994 and 2001 to 2003 rexaminations. A total of 10,609 participants were eligible
for analyses.
The CIHDS. This study comprises 5,185 patients with
ischemic heart disease from Copenhagen University Hos-
pital during the period from 1991 to 2009 and 10,368
controls without ischemic heart disease matched by age and
sex from the CGPS. Besides a diagnosis of ischemic heart
disease, these cases also had stenosis or atherosclerosis on
coronary angiography and/or positive results on exercise
electrocardiography.
Ischemic heart disease. Information on diagnoses of isch-
emic heart disease (World Health Organization Interna-
tional Classification of Diseases-Eighth Revision, codes 410
to 414; International Classification of Diseases-Tenth Re-
vision, codes I20 to I25) were collected from 1976 through
2010 by reviewing all hospital admissions and diagnoses
entered in the national Danish Patient Registry and all
causes of death entered in the national Danish Causes of
Death Registry, as previously described (1).
Laboratory analyses. Nonfasting total cholesterol, triglyc-
erides, and HDL cholesterol were measured using colori-
metric assays (Boehringer Mannheim, Mannheim, Ger-
many; Konelab, Thermo Fisher Scientific, Waltham,
Massachusetts). LDL cholesterol was calculated using the
Friedewald equation when plasma triglycerides were 4.0
mol/l and otherwise measured directly (Konelab). Non-
asting remnant cholesterol was calculated as nonfasting
otal cholesterol minus HDL cholesterol minus LDL
holesterol.
enotypes. Genotyping was performed using TaqMan
Applied Biosystems, Carlsbad, California) or by restriction
nzyme assays. Genotypes were verified by genotyping of
andomly selected samples of each variant using 2 different
ethods (TaqMan plus sequencing or restriction enzyme
ssay). Call rates for genotypes were 99.9% for all assays.
ther covariates. Smokers were defined as current smok-
rs. Hypertension was defined as systolic blood pressure
140 mm Hg (135 mm Hg for patients with diabetes),
iastolic blood pressure 90 mm Hg (85 mm Hg for
atients with diabetes), and/or the use of antihypertensive
edications prescribed specifically for hypertension. Lipid-
owering therapy was self-reported.
tatistical analysis. Data were analyzed using Stata/SE
ersion 11.2 (StataCorp LP, College Station, Texas). Two-
ided p values 0.05 were considered statistically signifi-
ant. Non-normally distributed variables were log trans-
ormed to approach a normal distribution. Chi-square tests
ere used to evaluated Hardy-Weinberg equilibrium.
In the prospective CGPS, CCHS, and CIHDS controls
ombined, Cox proportional hazards regression models with
ge as the time scale were used to estimate hazard ratios for
schemic heart disease by lipoproteins in quintiles; patients
iagnosed with ischemic heart disease before study entry
ere excluded, and those dying or emigrating during
ollow-up were censored at their deaths or emigration dates,
espectively. Multivariate adjustment was performed for age,
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January 29, 2013:427–36 Remnants and Ischemic Heart Diseasesex, smoking, hypertension, time since last meal, time of day
for blood sampling, and lipid-lowering therapy. Analyses
were purposely not adjusted for variables that in themselves
through biological pathways affect lipoprotein levels, such as
body mass index, alcohol consumption, and diabetes. Con-
ventional hazard ratios and confidence intervals (CIs) were
corrected for regression dilution bias using a nonparametric
method (15), using lipoprotein values from 4,253 individ-
als without lipid-lowering therapy participating in both the
991 to 1994 and 2001 to 2003 examinations of the CCHS;
his correction helps avoid underestimation of risk esti-
Figure 1 Remnant Cholesterol, Time Since Last Meal, and Tim
Remnant cholesterol as a function of time since last meal and time of day for blo
Characteristics of the Participants in the 3 StudiesTable 1 Characteristics of the Participants in the 3 Studies
Variable CGPS CCHS CIHDS
Number of participants 47,351 10,609 15,553
Women 28,806 (61%) 5,886 (55%) 4,418 (29%)
Age (yrs) 55 (46–65) 59 (46–69) 63 (56–71)
Triglycerides (mmol/l) 1.4 (1.0–2.1) 1.5 (1.1–2.2) 1.6 (1.1–2.3)
Remnant cholesterol
(mmol/l)
0.6 (0.4–0.9) 0.7 (0.5–1.0) 0.7 (0.5–1.0)
HDL cholesterol (mmol/l) 1.6 (1.3–1.9) 1.5 (1.2–1.9) 1.4 (1.1–1.8)
LDL cholesterol (mmol/l) 3.2 (2.6–3.8) 3.7 (3.0–4.5) 3.2 (2.6–3.9)
Hypertension 32,081 (68%) 5,075 (48%) 7,741 (78%)*
Smoking, current 9,919 (21%) 4,589 (49%) 2,193 (23%)*
Statin use 4,620 (10%) 87 (1%) 1,008 (10%)*
Ischemic heart disease 4,582 (10%) 2,217 (21%) 5,185 (33%)
Data are from study enrolment from 2003 to 2009 for the CGPS, from the 1991 to 1994 or 2001
to 2003 examinations of the CCHS when deoxyribonucleic acid was collected, and from study
enrollment from 1991 to 2009 in the CIHDS. Data are expressed as median (interquartile range)
or as number of participants (percent). Number of participants varies slightly according to
availability of variables. To convert triglyceride values to milligrams per deciliter, multiply values in
millimoles per liter by 88. To convert cholesterol values to milligrams per deciliter, multiply values
in millimoles per liter by 38.6. *Values available only for controls.
CCHS Copenhagen City Heart Study; CGPS Copenhagen General Population Study; CIHDS
Copenhagen Ischemic Heart Disease Study; HDL  high-density lipoprotein; LDL  low-density
ipoprotein.mates, but it does not affect whether results are statistically
significant. Regression dilution ratios of 0.48, 0.63, 0.73, and
0.60 were computed for nonfasting remnant cholesterol, the
ratio of nonfasting remnant cholesterol to HDL cholesterol,
HDL cholesterol, and LDL cholesterol, respectively.
One-way analysis of variance was used to compare lipo-
protein levels as a function of genotypes in the CGPS,
CCHS, and CIHDS controls combined. Genotypes were
combined in 4 groups: 1) nonfasting remnant cholesterol–
increasing alleles (TRIB1 rs2954029, GCKR rs1260326,
nd APOA5 rs651821); 2) nonfasting remnant cholesterol–
ncreasing and HDL cholesterol–decreasing alleles (LPL
s1801177, LPL G188E, LPL rs268, and LPL rs328); 3) HDL
cholesterol–decreasing alleles (LIPC -480CT, ABCA1
N1800H, and ABCA1 R2144X), and, as a positive control;
4) LDL cholesterol–increasing alleles (APOB rs5742904,
LDLR W23X, LDLR W66G, LDLR W556S, and PCSK9
rs11591147). The p values for trends were estimated using
Cuzick’s extension of the Wilcoxon rank sum test.
Association of genotypes with observed risk for ischemic
heart disease was by logistic regression estimating age-
adjusted and sex-adjusted odds ratios in the CGPS, CCHS,
and CIHDS combined. Theoretically predicted risk was
estimated from changes in lipoprotein values and known
conventional associations of lipoproteins with ischemic
heart disease in the prospective study.
Potential causal relationships between genetically ele-
vated or reduced levels of the different lipoproteins and risk
for ischemic heart disease were assessed by instrumental
variable analyses using 2-stage least squares regression in an
additive model. Genotypes associated with specific lipopro-
tein traits (i.e., nonfasting remnant cholesterol) were in-
ay for Blood Sampling
pling. Values are medians with interquartile ranges (error bars).e of D
od sam
i

t
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Remnants and Ischemic Heart Disease January 29, 2013:427–36cluded as individual instruments in both first-stage and
second-stage regressions; thereby, each variant was weighted by
frequency and effect size. The strength of the separate and
combined instruments was evaluated by F statistics from the
first-stage regression, where an F statistic 10 indicates
sufficient strength to ensure the validity of the instrumental
variable analysis (13). R2 values as percentages were used
as a measure of the contribution of genotypes to the
variation in the different lipoprotein levels. Lipoprotein
values were not available for all cases in the CIHDS (7.6%
missing) and were therefore imputed from age, sex, geno-
types, and the known distribution of lipoproteins in the
CGPS and the CCHS. The same was done for participants
from the CGPS (7.4%) and the CCHS (0.6%) using
lipid-lowering therapy; however, if subjects missing lipoprotein
values or on lipid-lowering therapy were excluded instead,
results were similar to those reported. Causal estimates from
instrumental variable analysis were compared with observed
risk for ischemic heart disease from conventional epidemiology
using the Bland-Altman method.
Results
Table 1 shows baseline characteristics of participants in the
3 studies. Participants in the CIHDS were older and more
often men than in the CGPS and the CCHS. Genotype
distributions for all studies were in Hardy-Weinberg equi-
librium (p  0.10).
Remnant cholesterol. Remnant cholesterol levels changed
slightly as a function of time since last meal and time of day
for blood sampling and had median levels of 0.55 mmol/l
during fasting and 0.67 mmol/l at 3 to 4 h after the last meal
(Fig. 1); the highest and lowest levels were seen at 1 and 7
PM, respectively. Increased levels of plasma triglycerides
were associated with increased levels of remnant cholesterol
and with reduced levels of HDL cholesterol, while the
association with LDL cholesterol was less pronounced (Fig. 2,
top). Remnant cholesterol levels were highly correlated with
nonfasting triglyceride levels (R2  0.96, p  0.001),
nversely correlated with HDL cholesterol levels (R2 
0.45, p  0.001), and less correlated with LDL choles-
erol levels (R2  0.12, p  0.001) (Fig. 2, bottom).
Risk for ischemic heart disease: observational estimates.
Associations of lipoproteins in quintiles with risk for isch-
emic heart disease in the CGPS, CCHS, and CIHDS
controls combined in a prospective design are shown in
Figure 3. Observational hazard ratios for the fifth versus first
quintiles were 2.3 (95% CI: 1.7 to 3.1) for increasing
nonfasting remnant cholesterol, 2.6 (95% CI: 2.1 to 3.2) for
increasing ratio of nonfasting remnant cholesterol to
HDL cholesterol, 2.5 (95% CI: 2.1 to 3.0) for decreasing
HDL cholesterol, and 1.8 (95% CI: 1.4 to 2.2) for
increasing LDL cholesterol.
Genotypes and lipoprotein levels. Lipoprotein levels as a
function of increasing number of lipoprotein-increasing and
lipoprotein-decreasing alleles for the CGPS, CCHS, andCIHDS controls combined are shown in Figure 4 for
groups of genotypes with similar effects. Corresponding effects
of the individual genotypes are shown in Online Figure 1.
For nonfasting remnant cholesterol alone, 3 to 6 versus 0
or 1 alleles were associated with 15% (0.10 mmol/l [4
mg/dl]) elevated nonfasting remnant cholesterol and 19%
elevated ratio of nonfasting remnant cholesterol to HDL
cholesterol. HDL and LDL cholesterol differed only
slightly by genotype.
For nonfasting remnant cholesterol and HDL cholesterol
combined, 3 or 4 versus 0 or 1 alleles were associated with
22% (0.15 mmol/l [6 mg/dl]) elevated nonfasting remnant
cholesterol, 37% elevated ratio of nonfasting remnant cho-
lesterol to HDL cholesterol, and 11% (0.18 mmol/l [7
mg/dl]) reduced HDL cholesterol. LDL cholesterol differed
only slightly by genotype.
For HDL cholesterol alone, 2 or 3 versus 0 alleles were
associated with 8% (0.13 mmol/l [5 mg/dl]) reduced HDL
cholesterol; the ratio of nonfasting remnant cholesterol to
Figure 2 Associations and Correlations of
Lipoprotein Cholesterol and Triglycerides
(Top) Lipoprotein cholesterol as a function of increasing levels of nonfasting
triglycerides. (Bottom) Correlation matrix of lipids and lipoproteins. Top panel
reproduced with modifications, with permission, from Nordestgaard and
Tybjærg-Hansen (10) and from Chapman et al. (2). HDL  high-density
lipoprotein; LDL  low-density lipoprotein.HDL cholesterol changed accordingly. Although nonfast-
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January 29, 2013:427–36 Remnants and Ischemic Heart Diseaseing remnant cholesterol decreased slightly as a function of
genotype, this was in the opposite direction of the usual
inverse association between reduced HDL cholesterol and
elevated nonfasting remnant cholesterol (2–4). LDL cho-
esterol did not differ by genotype.
For LDL cholesterol alone, 3 versus 0 or 1 alleles were
ssociated with 90% (2.66 mmol/l [103 mg/dl]) elevated
DL cholesterol. Other lipoprotein classes did not differ by
enotype.
enotypes and risk for ischemic heart disease. Assuming
hat each of the lipoproteins is causally associated with risk
or ischemic heart disease, we would theoretically expect
enetically elevated or reduced levels to be associated with
isk for ischemic heart disease in the same direction as
bserved for conventional lipoprotein levels, as shown in
igure 3. For nonfasting remnant cholesterol alone, for
onfasting remnant cholesterol and HDL cholesterol com-
ined, and for LDL cholesterol alone, the observed associ-
tions of the genotypes with risk for ischemic heart disease
ere in the same direction and more pronounced than the
heoretically predicted risk for ischemic heart disease; however,
Figure 3 Risk for Ischemic Heart Disease: Observational Estim
Risk for ischemic heart disease as a function of lipoprotein levels in quintiles in th
and Copenhagen Ischemic Heart Disease Study controls combined. The p values a
tein; LDL  low-density lipoprotein.his was not the case for HDL cholesterol alone (Fig. 5). fFor nonfasting remnant cholesterol alone for 3 to 6 versus
or 1 alleles, the observed risk was increased by 15% (95%
I: 9% to 21%) and the theoretically predicted risk by 5%
95% CI: 4% to 6%) (Fig. 5). For nonfasting remnant
holesterol and HDL cholesterol combined for 3 or 4 versus
or 1 alleles, the corresponding risks were increased by 29%
95% CI: 18% to 42%) and 9% (95% CI: 7% to 11%).
owever, for HDL cholesterol alone for 2 or 3 versus 0
lleles, we observed no association with risk for ischemic
eart disease by genotype, despite a theoretically predicted
ncreased risk of 7% (95% CI: 5% to 8%). Finally, for LDL
holesterol alone for 3 versus 0 or 1 alleles, corresponding
isks were increased by 525% (95% CI: 314% to 845%) and
5% (95% CI: 29% to 63%).
Other risk factors for ischemic heart disease than lipoproteins
ere generally distributed equally among genotypes, confirming
hat the genotypes are not confounded (Online Table 1).
isk for ischemic heart disease: causal estimates. We
lso examined the potential causal association of the lipo-
roteins with risk for ischemic heart disease in instrumental
ariable analyses. For nonfasting remnant cholesterol alone,
pective Copenhagen General Population Study, Copenhagen City Heart Study,
trends across quintiles. CI  confidence interval; HDL  high-density lipopro-ates
e pros
re foror the ratio of nonfasting remnant cholesterol to HDL
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Remnants and Ischemic Heart Disease January 29, 2013:427–36cholesterol, and for LDL cholesterol alone, causal risk
estimates for genetically elevated levels were in the same
direction and higher than corresponding risk estimates for
corresponding increases in conventional plasma levels of the
same lipoproteins; however, this was not the case for HDL
cholesterol alone (Fig. 6).
The causal odds ratio for a 1 mmol/l (39 mg/dl) genetic
increase of nonfasting remnant cholesterol was 2.8 (95% CI:
1.9 to 4.2), with a corresponding observational hazard ratio
of 1.4 (95% CI: 1.3 to 1.5) (Fig. 6). For the ratio of
onfasting remnant cholesterol to HDL cholesterol, corre-
ponding values were 2.9 (95% CI: 1.9 to 4.6) causal and 1.2
95% CI: 1.2 to 1.3) observational for a 1-U increase.
owever for HDL cholesterol, corresponding values were
.7 (95% CI: 0.4 to 1.4) causal and 1.6 (95% CI: 1.5 to 1.7)
bservational for a 1-mmol/l (39 mg/dl) decrease. Finally
or LDL cholesterol, corresponding values were 1.5 (95%
I: 1.3 to 1.6) causal and 1.1 (95% CI: 1.1 to 1.2)
bservational for a 1 mmol/l (39 mg/dl) increase.
Results were similar for a 1 standard deviation increase or
Figure 4 Genotypes and Lipoprotein Levels
Lipoprotein levels as a function of genotype in allele counts in the Copenhagen Ge
Disease Study controls combined. Genetic variants included in each lipoprotein gr
bars, percent change in lipoprotein levels, and p values for trends across allele co
protein; LDL  low-density lipoprotein.ecrease in genetic and plasma levels of the lipoproteins aOnline Fig. 2). Online Figure 3 illustrates that all genetic
ariants separately and combined for each lipoprotein stud-
ed were valid instruments (F statistics 10). Figure 6
hows causal odds ratios for the CGPS, CCHS, and
IHDS combined; however, analyzing these studies sepa-
ately gave similar results (Online Fig. 4).
iscussion
his study suggests that a 1 mmol/l (39 mg/dl) increase in
onfasting remnant cholesterol is associated with a 2.8-fold
ausal risk for ischemic heart disease, independent of re-
uced HDL cholesterol. These findings are novel.
That the causal risk for ischemic heart disease was higher
han the observational risk for elevated nonfasting remnant
holesterol suggests that lifelong exposure through geneti-
ally elevated levels may have a larger effect on risk than
uggested from observational data alone. This is in accor-
ance with parallel results for LDL cholesterol in present
Population Study, Copenhagen City Heart Study, and Copenhagen Ischemic Heart
e shown in brackets. Columns show mean lipoprotein levels with standard error
Participants using lipid-lowering therapy were excluded. HDL  high-density lipo-neral
oup ar
unts.nd former studies (16,17).
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January 29, 2013:427–36 Remnants and Ischemic Heart DiseaseMechanistically, the explanation for a causal effect of
elevated nonfasting remnant cholesterol on ischemic heart
disease risk could be that remnants (i.e., triglyceride-rich
lipoproteins) enter and get trapped in the intima of the
arterial wall (18,19). Like LDL trapping in the intima, this
would lead to the accumulation of intimal cholesterol,
atherosclerosis, and ultimately ischemic heart disease (2,9).
nlike LDL, remnants and triglyceride-rich lipoproteins
ay not need to be oxidized to be taken up by macrophages
o cause foam cell formation and atherosclerosis (20).
Previous case-control (21–31) and prospective (32–36)
tudies have also found observationally that elevated rem-
ant cholesterol is associated with increased risk for cardio-
ascular disease. However, these studies were relatively
mall and, unlike the present study, were unable to investi-
ate the causality of remnant cholesterol, because of con-
ounding by various cardiovascular risk factors and because
f the inverse association with reduced HDL cholesterol
2,10). To circumvent these problems, on one hand, we used
he Mendelian randomization approach to avoid confound-
ng from other cardiovascular risk factors: genetically deter-
Figure 5 Genotypes and Risk for Ischemic Heart Disease
Theoretically predicted risk and observed risk for ischemic heart disease as a func
HDL  high-density lipoprotein; LDL  low-density lipoprotein.ined levels of lipoproteins are present from birth and are therefore generally not confounded by other risk factors
13,14). On the other hand, by using carefully selected
enetic variants, we were able to deduct the causality of
ipoproteins by using genetic variants as instruments. Vari-
nts causing only lifelong elevated nonfasting remnant
holesterol were associated with increased risk for ischemic
eart disease. The same was seen for variants causing both
ifelong elevated nonfasting remnant cholesterol and re-
uced HDL cholesterol; however, variants causing only
ifelong reduced HDL cholesterol were not associated with
ncreased risk for ischemic heart disease. Taken together,
his implies that it must be the elevated nonfasting remnant
holesterol and triglyceride-rich lipoproteins that are caus-
lly related to increased risk for ischemic heart disease.
In our study, remnant cholesterol was determined in the
onfasting state and thus included cholesterol in all
riglyceride-rich lipoproteins, that is, very low-density lipo-
roteins, intermediate-density lipoproteins, and chylomi-
ron remnants combined. By using nonfasting remnant
holesterol calculated as nonfasting total cholesterol minus
DL cholesterol minus LDL cholesterol, remnant choles-
f genotypes in number of alleles. CI  confidence interval;tion oerol can be calculated directly from a standard lipid profile,
t434 Varbo et al. JACC Vol. 61, No. 4, 2013
Remnants and Ischemic Heart Disease January 29, 2013:427–36provided it is taken in the nonfasting state, as has been
recommended in Denmark since 2009. Thus, the presently
used calculated nonfasting remnant cholesterol comes at no
extra cost and is easily available.
The Mendelian randomization approach has potential
limitations, with the most important being pleiotropy of the
genetic variants used; that is, the genetic variants may affect
risk for ischemic heart disease through mechanisms other
than their effects on lipoprotein levels. For a proper Men-
delian randomization study, a variant that exclusively affects
plasma remnant cholesterol is needed. Because remnant
cholesterol is the result of multiple interrelated metabolic
processes involving many genes, an ideal variant that affects
only remnant cholesterol simply may not exist. Some
pleiotropic effects are evident for the 3 genetic variants
associated with remnant cholesterol and risk for ischemic
heart disease. From previous studies, it is known that
TRIB1 and APOA5 are also associated with HDL choles-
Figure 6 Causal and Observational Risk Estimates for Ischemic
Observational risk estimates in hazard ratios for a 1 mmol/l or a 1 ratio unit incre
General Population Study, Copenhagen City Heart Study, and Copenhagen Ischem
sion, time since last meal, time of day for blood sampling, and lipid-lowering thera
genetic lipoprotein levels in odds ratios are from the Copenhagen General Populat
Study combined, estimated by instrumental variable analyses. The p values are fo
between observational and causal estimates. CI  confidence interval; HDL  higerol and LDL cholesterol and GCKR with HDL choles-terol, fasting glucose levels, and risk for diabetes (37,38).
Most important, remnant cholesterol is directly related to
plasma triglycerides, because remnant cholesterol is the
cholesterol content of triglyceride-rich lipoproteins. How-
ever, because elevated triglycerides per se are unlikely to be
the direct cause of ischemic heart disease (2,8), the choles-
terol content of the triglyceride-rich lipoproteins is more
likely to be the cause of the risk marked by high triglycer-
ides. However, when we studied nonfasting plasma triglyc-
erides instead of nonfasting remnant cholesterol, results and
conclusions were largely similar (data not shown). Except
for triglycerides and other components of triglyceride-rich
lipoproteins, the presently used variants were not associated
to any large extent with other known risk factors, and
choosing more than 1 variant from different genes on
different chromosomes makes it unlikely that the variants
have the same pleiotropic effects (14). Nevertheless, rather
than remnant cholesterol per se, it is possible that
rt Disease
decrease in plasma lipoprotein levels are from the prospective Copenhagen
rt Disease Study controls combined, adjusted for age, sex, smoking, hyperten-
usal risk estimates for a 1 mmol/l or a 1 ratio unit increase or decrease in
udy, Copenhagen City Heart Study, and Copenhagen Ischemic Heart Disease
ficance of risk estimates, and p values for comparison are for differences
ity lipoprotein; LDL  low-density lipoprotein.Hea
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h-denstriglyceride-rich lipoprotein particles per se or other unmea-
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being causal for ischemic heart disease on the basis of our
findings.
Also, it could be argued that a relatively larger population
variation in remnant cholesterol compared with HDL and
LDL cholesterol would make it easier to detect associations
of genetic variants with remnant cholesterol; however,
because the variation over time was larger for remnant
cholesterol than for HDL and LDL cholesterol, with
regression dilution ratios of 0.48, 0.73, and 0.60, respec-
tively, it is more likely that it is the opposite; that is, it is
more difficult to detect genetic variation associated with
remnant cholesterol than with HDL and LDL cholesterol.
Furthermore, analyses are limited to a number of genetic
variants and genes, for example, 4 variants in LPL for
remnant cholesterol and HDL cholesterol, variants in 2
genes for HDL cholesterol, and variants in 3 genes for LDL
cholesterol. Because different biological pathways lead to
variability in these lipid fractions, the interpretation of the
results is limited to the processes regulated by the genes
included in the analysis. For HDL cholesterol, Mendelian
randomization studies do not support a casual relationship
between common genetic variants near ABCA1, LCAT,
LIPC, or LIPG (39–42), but it is possible that genetic
variation altering the expression or function of other genes
in the HDL pathway, such as CETP and APOA1, might
alter risk for ischemic heart disease. Finally, because we
studied white subjects only, our results may not necessarily
apply to other races.
Strengths of our study include sufficient statistical power
and no bias from admixture, because of the large sample size
of all white subjects of Danish descent. Another strength of
the present study is the control for the validity of the study
design by the inclusion of a positive LDL cholesterol
control in all analyses; LDL cholesterol is well documented
as a causal risk factor for ischemic heart disease (10,16,43).
Finally, although remnant cholesterol varies slightly more
than LDL cholesterol in the same subjects over 10 years
(compare regression dilution ratios of 0.48 vs. 0.60), we
corrected for this regression dilution bias for all lipoproteins.
Conclusions
A 1 mmol/l (39 mg/dl) increase in nonfasting remnant
cholesterol is associated with a 2.8-fold causal risk for
ischemic heart disease, independent of reduced HDL cho-
lesterol. This implies that the elevated cholesterol content of
triglyceride-rich lipoprotein particles causes ischemic heart
disease. However, because we cannot totally exclude pleio-
tropic effects of the genetic variants studied, our findings
need to be confirmed using additional genetic variants
and/or randomized intervention trials. These findings may
help direct future efforts to reduce cardiovascular disease
beyond the reduction achieved using statins. The focus of
future intervention studies should be not only on lowering
LDL cholesterol levels but also on lowering nonfastingremnant cholesterol levels and triglyceride-rich lipoproteins,
or alternatively on reduction in nonfasting apolipoprotein B
or non-HDL cholesterol, both of which include remnant or
triglyceride-rich lipoproteins.
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